11月11日,艾伯维宣布其用于治疗精神病症状急性加重的精神分裂症新药Emraclidine的两项EMPOWER试验未达到其主要终点,即与安慰剂相比,其在改善PANSS总分方面没有统计学上的显著差异。受此消息影响,艾伯维当日股价下跌超12%,而与此同时,同处“精神分裂症”赛道的BMS股价也因Emraclidine的失败而上涨约12%。据悉,Emraclidine作为一种毒蕈碱M4受体的正变构调节剂,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.